Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients

A recombinant fusion protein linking coagulation factor IX (FIX) with human albumin (rIX-FP) has been developed to facilitate hemophilia B treatment by less frequent FIX dosing. This first-in-human dose-escalation trial in 25 previously treated subjects with hemophilia B (FIX ≤ 2 IU/dL) examined the...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Santagostino, Elena, Negrier, Claude, Klamroth, Robert, Tiede, Andreas, Pabinger-Fasching, Ingrid, Voigt, Christine, Jacobs, Iris, Morfini, Massimo
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Hematology 2012
Témata:
Clinical Trials and Observations
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3448255/
https://ncbi.nlm.nih.gov/pubmed/22859609
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-05-429688
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky